Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Monika Karla Graeser, Oleg Gluz, Christine zu Eulenburg, Sherko Kuemmel, Matthias Christgen, Rachel Wuerstlein, Hans Heinrich Kreipe, Peter Schmid, Marc Thill, Michael Wilhelm Braun, Claudia Schumacher, Joke Tio, Johannes Schumacher, Andreas D. Hartkopf, Chrisitan Schem, Kerstin Luedtke-Heckenkamp, Felix Hilpert, Ronald Kates, Ulrike Nitz, Nadia Harbeck
Institutions: Universität Hamburg, University Medical Center Hamburg-Eppendorf, Evangelisches Krankenhaus Bethesda Mönchengladbach, University Hospital Cologne, Women‘s Healthcare Group, Kliniken Essen-Mitte, Charité - Universitätsmedizin Berlin, Medizinische Hochschule Hannover, Ludwig-Maximilians-Universität München, Barts Cancer Institute, Agaplesion Markus Hospital, German Red Cross, Krankenhaus vom Roten Kreuz, University Hospital Münster, Bundeskriminalamt, University of Tübingen, Mammazentrum Hamburg, Krankenhaus Jerusalem, München Klinik
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4410812308